Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOFA-PREDICT in psoriatic arthritis
NL-OMON60830Phase 4Completed
- Sponsor
- University Medical Center Utrecht
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tofacitinib in psoriatic arthritis (PsA) (4 arms), sponsored by University Medical Center Utrecht. Primary endpoints: Minimal Disease Activity at week 16 and Baseline molecular network profile. Started May 2018; status: completed.
02
Drugs
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON60830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60830.